Summary

Biotech’s tape improved after JPM, but the panel called it “less negative,” not a genuine risk-on turn. Tim Opler tracked the XBI from roughly 86.5 on January 13 to a 94.7 high and about 92, while investors took comfort from RFK’s confirmation hearing, softer tariff rhetoric, and hopes for a lower 10-year yield. Yet defensive large caps and dividend payers still led, the sector trailed the S&P by 12%, and Paul Matteis scored sentiment as moving only “from a one to a three”; Brian Skorney likewise described it as less negative rather than positive.
Wall-crossed PIPEs preserve financing optionality for operators, though their effect on generalist participation remains disputed. Tim accepted them as “the price of doing business,” and Abe Ceesay said companies must preserve every funding route, while Daphne Zohar questioned whether preferential access ultimately damages the sector. Paul argued that generalists are already far from the sub-$2 billion companies using these deals. The deeper obstacle may be disclosure: specialists can investigate FDA correspondence, biomarkers, physicians, and trial sites while Tim contrasted biotech with AI, where “you don’t have to have a Ph.D. to buy NVIDIA stock.”
The 2025 M&A outlook strengthened as pharma commentary shifted from small add-ons toward materially larger capacity. After J&J called its Intra-Cellular acquisition a one-off, Pfizer said it had more than $10 billion for deals and Merck emphasized its own capacity; Tim expected a strong year based on the less-visible pipeline. Bain’s $3.3 billion Mitsubishi Tanabe transaction arrived during the show, while Jay Bradner’s framing was that cash and M&A firepower are abundant but supply-side dynamics matter.
GH Research’s Phase 2b result made psychedelics look increasingly developable, though functional unblinding and a device change remain consequential risks. In 81 randomized patients, the short-acting treatment produced a 15-to-16-point placebo difference on MADRS at day eight, versus the roughly three points often assumed in Phase 3 powering, and repeat dosing appeared safe with a high long-term remission rate. Paul nevertheless flagged a placebo arm with essentially no improvement and the need to bridge into a replacement delivery device currently under an FDA clinical hold.
Axsome’s Symbravo approval begins as a “show me” migraine launch whose opportunity may expand in two stages. The current data support patients inadequately served by triptans, but payer step requirements could constrain access; data that Abe believes may arrive later in 2025 among CGRP nonresponders could broaden both clinical utility and reimbursement. Paul’s caution was commercial rather than scientific: migraine is enormous, but Biohaven showed that winning it requires “a lot of muscle.”
Neurocrine’s guidance exposed the IRA Part D redesign as a potentially broader specialty-drug risk. Ingrezza was once thought to be a roughly $700 million product and now guides to at least $2.5 billion in 2025, yet the shift from roughly 20% growth to below 10% alarmed investors as plans issued more outright denials. Paul highlighted payer catastrophic-liability exposure rising from 15% to 60%; Brian countered that reduced patient out-of-pocket costs might eventually stimulate utilization and called the selloff an overreaction.
The Alumis–ACELYRIN combination showed how cash-rich mergers can finance development more efficiently than conventional follow-ons. ACELYRIN contributes about $400 million and the combined company should hold more than $700 million, carrying Alumis through multiple catalysts despite issuing roughly 45 million shares. Brian calculated that the economics resemble a roughly $9-per-share offering versus the transaction’s approximately $6.50 price, while Tim compared the skepticism to EQRx’s ultimately successful merger into Revolution Medicines.
Amgen’s Pavblu launch turned Eylea biosimilar risk from a theoretical concern into a live erosion story for Regeneron. Pavblu generated $31 million in its first nine weeks, while Regeneron was already contending with a slower Eylea HD switch and a falling share price. Against a roughly $9 billion product, Regeneron’s dividend and enlarged buyback signaled corporate maturity—but management’s refusal to entertain another Eylea question dramatized the credibility cost of defensiveness.

Deep dive

1. Biotech sentiment recovered, but risk appetite did not

Tim’s market marker was the XBI: roughly 86.5 on January 13, a 94.7 high, and about 92 during the discussion. Investor conversations in Utah felt “less negative,” helped by RFK’s confirmation hearing, tariff de-escalation, and official interest in lowering the 10-year yield.
Paul still saw defensive positioning, limited appetite for binary high-science companies, and better demand for profitable or lower-risk names. Successful catalysts could finance, but sentiment remained below its five-year average.
Brian noted that JPM included consecutive declines of about 2.5% despite sizable M&A, and biotech still trailed the S&P by 12%. Tim described sentiment as moving from two to four out of ten; Paul preferred “from a one to a three,” while Brian likewise characterized the shift as less negative rather than positive.

2. Specialist financing solves today’s problem while its effect on generalist participation remains disputed

Daphne framed wall-crossed PIPEs as an uncomfortable bargain: one specialist said outperforming generalists was his job and he would accept any advantage; another considered the practice “borderline unethical” but would not decline access to the data.
Tim’s concession was practical: specialists keep companies funded, and their preferred discount or structure can become “the price of doing business.” Abe’s operator view was similarly blunt—whatever the segmentation cost, difficult markets make financing optionality essential.
Brian’s pushback was that generalists are nowhere near the sub-$2 billion companies typically using these PIPEs. Paul added that broader participation is not automatically healthy: in 2015, many generalists buying gene-therapy stories probably did not understand the risks.
Tim located the structural problem in disclosure. Investors can be surprised by Phase 3 failures or complete response letters even when troubling FDA correspondence existed beforehand, leaving specialists to uncover reality through physician calls and clinical-site work. Brian’s conclusion was that generalists return through cyclical FOMO only after sector outperformance forces them back.

3. Pharma’s cash is plentiful, while supply-side dynamics shape M&A

Tim contrasted J&J’s warning that Intra-Cellular was a one-off and JPM’s emphasis on smaller add-ons with later earnings commentary: Pfizer cited more than $10 billion of M&A capacity, Merck discussed its firepower, and the less-visible pipeline suggested a strong 2025.
Confirmation arrived in real time when Bain’s $3.3 billion transaction for Mitsubishi Tanabe was reported as the show began. Tim highlighted Radicava’s potential to become a billion-dollar ALS product.
Bradner’s supply-side framing explained why cash alone does not guarantee deals: after one compelling CAR-T came “another 200”—how many are actually needed? He also described Chinese science as progressing from nonexistent, to fast follower, to genuinely innovative competitor.
The Alumis–ACELYRIN merger offered another capital route: more than $700 million of combined cash, including about $400 million from ACELYRIN, should fund costly psoriasis and lupus programs through several catalysts. Brian estimated economics resembling a $9-per-share raise, one Alumis could not execute conventionally near the transaction’s approximately $6.50 price.

4. GH Research delivered an unusually large efficacy signal with unusual trial risk

Paul called GH Research’s 81-patient Phase 2b an important transition from open-label evidence to randomized, placebo-controlled data. At the eight-day primary endpoint, the MADRS difference was 15–16 points; depression Phase 3 trials are often powered around three.
The longer-term design was unusually assertive: at scheduled visits, patients not in remission could simply be redosed rather than waiting through a four-to-six-week depressive episode. Repeat dosing appeared safe and could produce a high remission rate over six months.
The first caveat was obvious functional unblinding—the placebo group barely improved. The second was the future delivery-device change: GH expects to resolve the FDA clinical hold, and investors will want pharmacokinetic data showing that the results can bridge into the next study.
Daphne widened the lens beyond psychedelics. CNS trials require careful site selection, screening-to-baseline controls, exclusion of adjustment disorder, restrained assessments, and management of placebo expectations. Commercially, having a shaman present during a psychedelic session can have implications, yet Spravato’s two-hour, every-other-week visits, mixed randomized-study record, and approximately $1.2 billion annualized sales demonstrate real demand.

5. Symbravo’s migraine opportunity depends on access before scale

Abe welcomed Axsome’s AXS-07, branded Symbravo, as another example of a company overcoming a CMC-related complete response letter. “Drug development is not a linear process,” and neither is an NDA submission.
The initial opportunity is among patients inadequately served by triptans, but payers may still require those steps before granting access. Data Abe believed might arrive later in 2025 among CGRP nonresponders could create a second-stage expansion in clinical use and reimbursement.
Investors should therefore expect a “show me launch.” Paul agreed migraine is huge, but Biohaven’s spending demonstrated its capital intensity; Pfizer’s strategy depended on pushing the category into primary care, an ambition requiring substantial commercial muscle.

6. Neurocrine turned Part D redesign into an immediate valuation question

Paul put the disappointment in context: Ingrezza was once thought to be a roughly $700 million tardive-dyskinesia drug and now guides to $2.5–$2.6 billion for 2025. The shock was the abrupt move from around 20% growth to below 10%, not a failed franchise.
Neurocrine reported more payer resistance without materially changing its contracting strategy—more outright denials, not merely extra physician paperwork. That might reflect Teva competition, a roughly $4 billion class reaching a payer threshold, or a wider specialty-small-molecule problem.
Under the Part D redesign, Paul said plans’ share of catastrophic drug costs rises from 15% to 60% for the roughly half of Medicare patients outside Medicare Advantage. On a $100,000 drug, payer liability could increase by about $40,000.
Brian thought the quarter itself was fine and summarized the guidance sensitivity neatly: “If it was 2.6 to 2.7, I think the stock would be fine.” His unresolved counterweight was utilization—lower patient out-of-pocket costs might eventually stimulate greater use and change the economics.

7. Pavblu made Regeneron’s Eylea defense a live contest

Amgen’s Pavblu produced $31 million in nine weeks, a strong opening for the only Eylea biosimilar then launched after navigating the patent landscape. The result challenged the longstanding view that ophthalmologists would strongly prefer branded drugs and less-frequent injections.
Regeneron entered the contest with a slowing Eylea HD conversion and a share price already under pressure. Its roughly $18 billion cash balance, dividend, and larger repurchase authorization looked like the actions of a mature, highly profitable company.
The earnings-call optics cut the other way: after repeated Eylea questions, CEO Len declined one from a Bank of America analyst and moved her back in the queue. Daphne emphasized the stakes—Eylea is a roughly $9 billion product, and reimbursement incentives can accelerate biosimilar switching.

8. Credibility comes from showing the bear case before investors do

Abe distinguished development guidance from commercial guidance: revenue and prescriptions are more accessible to investors, while reimbursement and access create new variables as an R&D company matures. Realistic conservatism builds trust; insulting competitors does not, and he saw no patient or shareholder benefit in doing so.
Paul said unusual defensiveness often makes him feel that his skepticism is “onto something.” Conversely, companies that welcomed engagement after an unsupportive initiation sometimes proved to be better stock calls than he expected because their openness reflected confidence.
His preferred model was Steve Paul’s response after an encouraging muscarinic Phase 2 randomized controlled trial: genuine excitement paired with explicit caution about a single study and uncertain extrapolation to Alzheimer’s. Investors want management able to sell upside while remaining “a little bit paranoid.”
Brian cautioned that tone must be judged against each team’s history—some CEOs are naturally combative. Still, long holders asking hard questions are not necessarily shorts: Paul might see a favored stock as 75% likely to work while remaining “terrified” about the other 25%. Daphne relayed Josh Schimmer’s label for CEOs who never acknowledge problems: “everything-is-awesome CEOs.”

9. The Hims compounding dispute exposed a real access-versus-incentive conflict

Daphne attacked Hims’ Super Bowl commercial for “virtue signaling,” disparaging the drug industry, promoting an unregulated compounded version without fair balance, and benefiting from products developed by others. The Partnership for Safe Medicines had written to the FDA expressing concern.
Abe agreed that the advertising style was obnoxious but rejected the impression that compounders are uncontrolled garage operators. His countercase was access: lower online pricing can let another group obtain medicines it otherwise might not be able to access.
Daphne conceded that shortages and high prices created a legitimate role for compounding, while preserving the objection that companies can invest years and close to $1 billion in R&D only to see others exploit a temporary loophole. She said the issue deserved a fuller discussion.

Episode 131 - February 14, 2025 Episode 129 - January 31, 2025